To evaluate the ability of these synthesized compounds to inhibit KDM4A and to modulate methylation levels of lysine 9 and 36, we tested the molecules by in vitro enzymatic assay and in tumor cell lines. The gene discussed is KDM4A; the disease is neoplasm.